Pharmaceutical company Gilead Sciences may pay $246 million to settle a lawsuit over the delay in the release of generic drugs
Gilead Sciences commits to pay $246.75 million to customers who have purchased Atripla or Truvada, or generic versions of these drugs over the past five years